| Small-molecule inhibitors and biologics for palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis. | 2024 | American journal of clinical dermatology |
| Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis. | 2024 | Advances in Rheumatology |
| Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. | 2023 | The Cochrane Database of Systematic Reviews |
| Efficacy and safety of nail psoriasis targeted therapies: a systematic review. | 2023 | American Journal of Clinical Dermatology |
| Evaluation of the synovial effects of biological and targeted synthetic dmards in patients with psoriatic arthritis: a systematic literature review and meta-analysis. | 2023 | Internation Journal of Molecular Sciences |
| Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis of randomized clinical trials. | 2023 | Journal of the American Academy of Dermatology |
| Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis | 2023 | Rheumatology (Oxford) |
| Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis. | 2023 | Expert Review of Clinical Immunology |
| Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. | 2023 | Annals of the Rheumatic Diseases |
| Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling. | 2023 | Expert review of clinical pharmacology |
| Efficacy and safety of secukinumab for the treatment of psoriasis: a meta-analysis of pivotal phase III trials. | 2023 | Dermatology |
| Comparative efficacy of biologic disease-modifying anti-rheumatic drugs for non-radiographic axial spondyloarthritis: a systematic literature review and Bucher indirect comparisons. | 2023 | Rheumatology and therapy |
| Clinical and economic benefit of advanced therapies for the treatment of active ankylosing spondylitis | 2023 | Rheumatology and therapy |
| Biologics for pediatric moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. | 2022 | Journal of the German Society of Dermatology |
| Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: a systematic review and network meta-analysis. | 2022 | Pharmaceutics |
| Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular. dermatological, enthesitis and dactylitis outcomes. | 2022 | Rheumatic & Muscoskeletal Diseases |
| Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. | 2022 | Journal of Dermatological Treatment |
| Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. | 2022 | The Cochrane Database of Systematic Reviews |
| Biologics for pediatric psoriasis: a systematic review and meta-analysis. | 2022 | Pediatric dermatology |
| Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. | 2022 | Dermatology and therapy |
| Towards personalized medicine in psoriasis: current progress. | 2022 | Psoriasis |
| Comparative efficacy and safety of Janus Kinase inhibitors and secukinumab in patients with active ankylosing spondylitis: a systematic review and meta-analysis. | 2022 | Pharmacology |
| Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis. | 2022 | Frontiers in medicine |
| Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis. | 2022 | Advances in therapy |
| Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis. | 2022 | Inflammopharmacology |
| Evidence for the use of secukinumab in patients with radiographic and non-radiographic axial spondyloarthritis in the last 5 years. | 2022 | Rheumatology and therapy |
| Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis. | 2022 | Chinese medical journal |
| Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. | 2022 | Seminars in arthritis and rheumatism. |
| Real-life efficacy and drug continuation of secukinumab in treating moderate to severe plaque psoriasis in Aegean region of Turkey: a multicenter retrospective study and systematic review of the literature. | 2022 | Asian Pacific Journal of Allergy and Immunology |
| Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis. | 2021 | Dermatology and Therapy |
| Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis. | 2021 | European Review for Medical and Pharmacological Sciences |
| Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: a combined and updated meta-analysis. | 2021 | Journal of Clinical Pharmacy and Therapeutics |
| Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. | 2021 | Dermatologic Therapy |
| Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: a network meta-analysis. | 2021 | International Journal of Clinical Pharmacology and Therapeutics |
| Comparative efficacy and safety of secukinumab, ixekizumab, and tofacitinib in patients with active psoriatic arthritis showing insufficient response to tumor necrosis factor inhibitors. | 2021 | International Journal of Clinical Pharmacology and Therapeutics |
| A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains. | 2021 | Frontiers in Medicine |
| Dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real world: a systematic review. | 2021 | Dermatology and Therapy |
| Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. | 2021 | Clinical Rheumatology |
| Efficacy and safety of anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a meta-analysis. | 2021 | Monoclonal Antibodies in Immunodiagnosis and Immunotherapy |
| A pooled analysis reporting the efficacy and safety of secukinumab in male and female patients with ankylosing spondylitis. | 2021 | Rheumatology and therapy |
| Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis: pooled analysis of two phase 3 studies. | 2021 | Rheumatology and therapy |
| Secukinumab efficacy on enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal phase III studies. | 2021 | The Journal of rheumatology |
| Comparative efficacy and safety of secukinumab 75 mg, 150 mg, and 300 mg in patients with active ankylosing spondylitis. | 2021 | International journal of clinical pharmacology and therapeutics |
| Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis. | 2021 | Zeitschrift fur Rheumatologie |
| Short-term efficacy and safety of secukinumab for ankylosing spondylitis: a systematic review and meta-analysis of RCTs. | 2020 | Mediators of Inflammation |
| Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence. | 2020 | BioDrugs |
| Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. | 2020 | JAMA Dermatology |
| The effects of selected biologics and a small molecule on health-related quality of Life in adult plaque psoriasis patients: a systematic review and meta-analysis. | 2020 | PLoS One |
| Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis | 2020 | The British journal of dermatology |
| Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. | 2020 | Annals of the Rheumatic Diseases |
| Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis. | 2020 | The Journal of Rheumatology |
| Fourteen small molecule and biological agents for psoriatic arthritis: a network meta-analysis of randomized controlled trials. | 2020 | Medicine |
| Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis. | 2020 | Arthritis Research & Therapy |
| Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. | 2020 | Clinical and Experimental Rheumatology |
| Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses. | 2020 | Dermatology and Therapy |
| Short-term efficacy and safety of il-17, il-12/23, and il-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. | 2019 | Journal of Immunology Research |
| Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. | 2019 | Arthritis Research & Therapy |
| Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. | 2019 | Arthritis Research & Therapy |
| Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. | 2019 | PloS One |
| A cost-per-number needed to treat analysis assessing the efficiency of biologic drugs in moderate to severe plaque psoriasis. | 2019 | Actas Dermo-sifiliograficas |
